Hydralazine-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Asymptomatic and Renal-Restricted Presentation

Wan Tu
ADE
Barry Fayman
BDE
Stephen C. Ward
ABD
Yusufal Mamoon
CD
Sabiha S. Bandagi

Corresponding Authors: Wan Tu, e-mail: tuw@nychhc.org; Barry Fayman, e-mail: faymanb@nychhc.org

Conflict of interest: None declared

Patient: Female, 66-year-old
Final Diagnosis: Hydralazine induced ANCA-associated vasculitis
Symptoms: Asymptomatic
Medication: —
Clinical Procedure: —
Specialty: Nephrology • Rheumatology

Objective: Rare disease
Background: Hydralazine, a potent vasodilator widely used to treat hypertension, has been implicated in an increasing number of cases of drug-induced autoimmune diseases in recent years. However, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis secondary to hydralazine use has rarely been described and most reported cases involved multi-organ-related vasculitis, including skin and lung-kidney manifestations. ANCA-associated vasculitis is an immune-inflammatory condition characterized by necrotizing vasculitis with few or no immune deposits, predominantly affecting small vessels. The fact that the vasculitis is associated with hydralazine use and improves with discontinuation of hydralazine supports the diagnosis of hydralazine-induced disease. The case we report is a hydralazine-induced, ANCA-associated, pauci-immune crescentic glomerulonephritis with a presentation limited to the kidneys.

Case Report: A 66-year-old woman was admitted to the hospital for worsening renal function over a month with no symptoms. Serology work-up was significantly positive for antinuclear, perinuclear ANCA, anti-histone, anti-double-stranded DNA, anti-cardiolipin, and anti-myeloperoxidase antibodies. The patient ultimately underwent a kidney biopsy, which revealed pauci-immune crescentic glomerulonephritis. Her kidney function improved with cessation of hydralazine as well as therapy with pulse steroids.

Conclusions: Hydralazine is commonly prescribed to treat hypertension. Healthcare providers should be aware of potentially severe hydralazine-induced ANCA-associated vasculitis, which can present with various clinical manifestations. Serologic studies have indicated that it has features that overlap with lupus. Biopsy is helpful for making a definitive diagnosis and developing individual treatment plans. Early diagnosis, cessation of the offending drug, and initiation of immunosuppressive therapy are key for favorable prognosis.

Keywords: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis • Glomerulonephritis • Hydralazine

Full-text PDF: https://www.amjcaserep.com/abstract/index/idArt/931263
Background

Hydralazine-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a necrotizing vasculitis with few or no immune deposits that predominantly affects small vessels and it is associated with hydralazine use. The disease typically presents with multisystem involvement of organs such as the kidneys, lung, skin, mucosa, heart, blood, and joints; without prompt treatment, it can rapidly progress to organ failure [1]. The diagnosis mostly relies on serologic studies, with positivity for ANCA (anti-myeloperoxidase [MPO] and/or anti-proteinase 3 [PR3]) and tissue biopsy of involved organs showing pauci-immune vasculitis. Antinuclear (ANA), anti-histone, anti-double-stranded DNA (dsDNA), and anti-cardiolipin antibodies also can be positive and present with serologic features that overlap with systemic lupus erythematosus (SLE) [2]. However, only 3 studies have described the kidneys as the only organs involved in hydralazine-induced ANCA vasculitis [3-5]. Thus, the purpose of the present case report is to illustrate an asymptomatic and kidney-limited presentation of hydralazine-induced ANCA-associated vasculitis, which can be easily missed, and to highlight the work-up leading to the diagnosis and discuss a current evidence-based approach to this disease.

Case Report

A 66-year-old woman was hospitalized by her primary care physician because of worsening renal function. She had a 10-year history of hypertension and a 7-year history of type 2 diabetes mellitus and hyperlipidemia. Two years before, she had undergone a thyroidectomy for thyroid papillary carcinoma and had experienced postoperative hypothyroidism. She also had class I obesity. The patient had taken amlodipine, hydrochlorothiazide, and labetalol for 10 years; metformin for 7 years; hydralazine, losartan, and atorvastatin for 5 years; and levothyroxine for 2 years. There were no recent changes to these medications. During the past 5 years, control of the patient’s hypertension had been suboptimal, with a systolic blood pressure of 140 to 150; her diabetes was well controlled, with a hemoglobin A1C of 5.9 to 6.8.

On presentation, the patient was asymptomatic, afebrile, and had a blood pressure of 147/73 mmHg, heart rate of 86 bpm, and pulse oxygenation of 99 on room air. Her physical examination was unremarkable except for obesity. The initial laboratory work-up showed a white blood cell (WBC) count of 6.29×10⁹/L, hemoglobin of 8.0 g/dL, platelet count of 364×10⁹/L, serum creatinine of 3.99 mg/dL, blood urea nitrogen (BUN) of 41 mg/dL, an estimated glomerular filtration rate (eGFR) of 14 mL/min/1.73 m², potassium of 4.3 mmol/L, phosphorus of 6.3 mmol/L, sodium of 135 mmol/L, bicarbonate of 30 mmol/L, and venous pH of 7.403. Urinalysis showed a cloudy appearance, pH of 5.0, specific gravity of 1.017, 11 to 20 red blood cells (RBCs)/hpf, >50 WBCs/hpf, 300 mg/mL of protein, a few bacteria, and no casts. A chest X-ray showed mild enlargement of the cardiac silhouette. A renal ultrasound showed increased cortical echogenicity due to intrinsic renal parenchymal disease and no hydronephrosis.

A review of the results of outpatient laboratory testing in the past 4 years showed a baseline hemoglobin of 10.9 to 13 g/dL, creatinine level of 0.81 to 1.18 mg/dL, BUN of 7 to 19 mg/dL, and an eGFR of 59 to 88 mL/min/1.73 m²; testing for microalbumin in the urine was negative. In the last month, however, the patient’s kidney function had worsened and laboratory testing revealed a creatinine level of 2.05 mg/dL, BUN of 29 mg/dL, eGFR of 29 mL/min/1.73 m², and urine microalbumin of 1312.8 mg/g creatinine. The prior urinalysis had showed trace protein, 5 to 6 WBCs/hpf, and 11 to 20 RBCs/hpf. The patient’s kidney and thyroid function were within normal range and serology for hepatitis B and C and HIV was negative.

A urine culture performed in the hospital showed ≥3 organisms, which probably represented contamination of the collection. Serum protein electrophoresis and immunofixation studies did not identify any monoclonal bands. The patient’s parathyroid hormone level was 62 pg/mL, calcium 9.2 mL/dL, 25-hydroxy vitamin D 40.9 ng/mL, creatine kinase 119 U/L, plasma renin 14.5 pg/mL, and her serum aldosterone level was 62.7 ng/dL. Further urine studies revealed a sodium level of 46 mmol/L, urine creatinine of 111 mg/dL, urine protein of 365 mg/dL, and urine protein/creatinine ratio of 3.29. These variables were used to calculate fractional excretion of sodium (FeNa), which was 1.2%.

The patient’s serology results are shown in Table 1.

The patient was treated with gentle intravenous hydration, a transfusion of 1 unit of packed RBCs, 5 days of iron sucrose infusion after iron studies suggested that she had iron deficiency anemia, and sevelamer carbonate for hyperphosphatemia. Losartan and hydrochlorothiazide were stopped on the day of her admission and hydralazine was discontinued after the ANA and ANCA results were found to be positive.

Because of the presence of multiple positive autoimmune markers and the unclear etiology and prognosis of the patient’s kidney disease, a kidney biopsy was obtained and multiple cylindrical, pale tan soft tissue samples ranging in size from 0.1 cm to 1.7 cm in length and 0.1 cm in diameter were submitted. Light microscopy (Figure 1) indicated that of 23 glomeruli, 5 were obsolete, 9 contained cellular crescents, and 1 contained a fibrous crescent. There was some mild mesangial expansion and hypercellularity and a few glomeruli showed ischemic-type changes, but no endocapillary proliferation, wire
loops, or hyaline thrombi were seen. There was also variable thickening of the tubular basement membranes, moderate arteriosclerosis, and moderate parenchymal scarring with associated lymphoplasmacytic infiltrates. Immunofluorescence studies showed only segmental immune deposits in an area of scarring and weak, nonspecific mesangial staining with immune globulin (Ig) M and lack of significant staining for IgG, IgA, complement component (C) 1q or C3 (Figure 2). Electron microscopy showed glomeruli with ischemic-type changes and variable thickening of the glomerular basement membranes but no immune-type deposits. The diagnosis of pauci-immune crescentic glomerulonephritis was made. The mesangial expansion and thickening of the glomerular and tubular basement membranes were compatible with early diabetic changes.

The patient’s kidney function started to improve 3 days after hydralazine was discontinued, as evidenced by a serum creatinine level of 3.01 mg/dL, BUN of 30 mg/dL, and eGFR of 19 mL/min/1.73 m². After results of the kidney biopsy were received, the patient was started on methylprednisolone with pulsed dosing, 1000 mg daily for 3 days, and discharged home to take prednisone, 20 mg twice daily, and

| Test                                         | Titer/unit | Reference range | Result |
|----------------------------------------------|------------|-----------------|--------|
| Antinuclear antibody (ANA)                   | 1: 2560 (IFA homogeneous pattern) | <1: 80 | Positive |
| Anti-double stranded DNA (dsDNA)             | EIA 89 IU/mL | EIA ≤29 IU/mL | Positive |
| Anti-Smith antibody                          | ENA <0.2 Al | ENA ≤0.9 Al | Negative |
| Anti-ribonuclear protein (RNP) antibody      | ENA 0.3 Al | ENA ≤0.9 Al | Negative |
| Anti-chromatin antibody                      | 2.4 Al | ≤0.9 Al | Positive |
| Total complement, ch50                       | 67 U/mL | 42-95 U/mL | Normal |
| Complement component C3 (C3)                | 136 mg/dL | 81-157 mg/dL | Normal |
| Complement component C4 (C4)                | 26 mg/dL | 13-39 mg/dL | Normal |
| Cytoplasmic antineutrophil cytoplasmic antibody (cANCA) | Negative | Negative |
| Perinuclear antineutrophil cytoplasmic antibody (pANCA) | >1: 1280 | Negative | Positive |
| Atypical anti-neutrophilic cytoplasmic antibody | Negative | Negative |
| Anti-proteinase 3 (PR3) antibody             | 132.2 U | ≤20.0 U | Positive |
| Anti-myeloperoxidase (MPO) antibody          | 104.0 U | ≤20.0 U | Positive |
| Rheumatoid factor                            | <10 IU/mL | 0-13 IU/mL | Negative |
| Anti-cyclic citrullinated peptide (CCP) antibody | ≤8 U | ≤19 U | Negative |
| Anti-centromere antibody                     | ≤0.2 Al | ≤0.9 Al | Negative |
| Anti-histone antibody                        | 3.2 U | 0.0-0.9 U | Positive |
| Anti-cardiolipin antibody                    | Negative | Positive |
| Anti-scleroderma (sc70) antibody             | <0.2 Al | ≤0.9 Al | Negative |
| Immunoglobulin G (IgG)                      | 1581 mg/dL | 610-1660 mg/dL | Normal |
| Immunoglobulin M (IgM)                      | 155 mg/dL | 35-242 mg/dL | Normal |
| Beta 2 glycoprotein 1 IgG Ab                 | 5.1 SGU | ≤20.0 SGU | Negative |
| Beta 2 glycoprotein 1 IgM Ab                 | 31.1 SMU | ≤20.0 SMU | Positive |
| Cryoglobulin                                 | Negative | Negative |
| Anti-glomerular basement membrane (GBM) antibody | 3 | 0-20 | Negative |

EIA – enzyme immunoassay; ENA – epithelial cell-derived neutrophil attractant; IFA – indirect immunofluorescence assay.

loops, or hyaline thrombi were seen. There was also variable thickening of the tubular basement membranes, moderate arteriosclerosis, and moderate parenchymal scarring with associated lymphoplasmacytic infiltrates. Immunofluorescence studies showed only segmental immune deposits in an area of scarring and weak, nonspecific mesangial staining with immune globulin (Ig) M and lack of significant staining for IgG, IgA, complement component (C) 1q or C3 (Figure 2). Electron microscopy showed glomeruli with ischemic-type changes and variable thickening of the glomerular basement membranes but no immune-type deposits. The diagnosis of pauci-immune crescentic glomerulonephritis was made. The mesangial expansion and thickening of the glomerular and tubular basement membranes were compatible with early diabetic changes.

The patient’s kidney function started to improve 3 days after hydralazine was discontinued, as evidenced by a serum creatinine level of 3.01 mg/dL, BUN of 30 mg/dL, and eGFR of 19 mL/min/1.73 m². After results of the kidney biopsy were received, the patient was started on methylprednisolone with pulsed dosing, 1000 mg daily for 3 days, and discharged home to take prednisone, 20 mg twice daily, and
mycophenolate mofetil, 1000 mg daily. On the day of discharge, the patient’s kidney function had improved further to a creatinine level of 2.67 mg/dL, BUN of 42 mg/d, and an eGFR of 22 mL/min/1.73 m².

The patient subsequently followed up with our nephrology and rheumatology clinics. She had continued to take prednisone, 20 mg twice daily and mycophenolate mofetil, 1000 mg daily, and remained asymptomatic. Laboratory testing performed 6 weeks after discharge showed an improved serum creatinine level of 2.36 mg/dL, BUN of 57 mg/dL, and eGFR of 24 mL/min/1.73 m². Urinalysis showed a clear appearance, pH of 5.5, specific gravity of 1.016, 4 to 6 RBCs/hpf, 5 to 6 WBCs/hpf, >1000 mg/mL protein, no bacteria, and no casts.

Figure 1. Light microscopy reveals a glomerulus with crescentic glomerulonephritis and mild mesangial expansion.

Figure 2. Immunofluorescence profile with staining for A: IgM statin, B: IgG statin, C: IgA statin, D: C3 statin, E: C1q statin. IG – immune globulin.
Because the patient's kidney function was not back to baseline and she had worsening proteinuria, her dosage of mycophenolate mofetil was increased to 1000 mg twice daily. She continues to follow up with our clinics.

Interventions at specific time points and outcomes are shown in Table 2.

### Table 2. Interventions at specific time points and outcomes.

| Intervention                  | Adhesion | Post-admission |
|--------------------------------|----------|----------------|
| Serology resulted             | PO prednisone started | Mycophenolate dose increased |
| Hydralazine discontinued      | Kidney biopsy obtained  |
| pANCA                          | Neg      | Neg            |
| cANCA                          | Neg      | Neg            |
| Blood urea nitrogen (mg/dL)    | 18       | 14             |
| Creatinine (mg/dL)             | 0.91     | 1.05           |
| GFR (mL/min/1.73 m2)           | 81       | 65             |
| Blood                          | Neg      | Large          |
| Protein (mg/mL)                | 300      | >1000          |
| White blood cells (/hpf)       | 5-6      | >50            |
| Red blood cells (/hpf)         | 11-20    | 11-20          |
| ESR (mm/h)                     | 30       |
| CRP (mg/L)                     | <0.1     |
| Ferritin (ng/mL)               | 37       | 120            |
| pANCA                          | 1: 1280  | 1: 1280        |
| cANCA                          | Neg      | Neg            |
| Renal function                 | 5 Years Ago | 4 Months Ago | 1 Month Ago | Day 0 | Day 3 | Day 4 | Day 7 | Day 9 | Day 11 | 6 Weeks |
| Blood urea nitrogen (mg/dL)    | 18       | 14             | 27         | 41    | 41    | 30    | 27    | 42    | 57    |
| Creatinine (mg/dL)             | 0.91     | 1.05           | 2.05      | 3.99  | 3.62  | 3.01  | 2.81  | 2.67  | 2.36  |
| GFR (mL/min/1.73 m2)           | 81       | 65             | 29        | 14    | 15    | 19    | 20    | 22    | 24    |
| Blood                          | Neg      | Large          |
| Protein (mg/mL)                | 300      | ≥1000          |
| White blood cells (/hpf)       | 5-6      | >50            |
| Red blood cells (/hpf)         | 11-20    | 11-20          |
| ESR (mm/h)                     | 30       |
| CRP (mg/L)                     | <0.1     |
| Ferritin (ng/mL)               | 37       | 120            |
| pANCA                          | 1: 1280  | 1: 1280        |
| cANCA                          | Neg      | Neg            |
| Intervention                  | Serology resulted | Hydralazine discontinued | Kidney biopsy obtained | PO prednisone and mycophenolate started | Mycophenolate dose increased |
| Hydralazine discontinued      | Kidney biopsy obtained  |
| pANCA                          | 1: 1280  | 1: 1280        |
| cANCA                          | Neg      | Neg            |

Because the patient’s kidney function was not back to baseline and she had worsening proteinuria, her dosage of mycophenolate mofetil was increased to 1000 mg twice daily. She continues to follow up with our clinics.

Interventions at specific time points and outcomes are shown in Table 2.

### Discussion

Drug-induced, ANCA-associated vasculitis is a group of immunoinflammatory conditions characterized by necrotizing vasculitis with few or no immune deposits, which predominantly affect small vessels and are associated with use of certain medications. The pathophysiology of the disease resembles microscopic polyangiitis because granulomatous inflammation is usually absent. The fact that the vasculitis is associated with use of specific drugs and improves with discontinuation of those agents supports the diagnosis of drug-induced disease.

Recently, more cases of drug-induced ANCA-associated vasculitis are being reported. The culprits include anti-thyroid drugs (propylthiouracil, methimazole, carbimazole, and benzylthiouracil), tumor necrosis factor inhibitors (etanercept, infliximab, adalimumab, and golimumab) and hydralazine, rituximab, minocycline, and montelukast. Other drugs that have been shown to have a possible association with ANCA-associated vasculitis include cefotaxime, nitrofurantoin, trimethoprim-sulfamethoxazole, vancomycin, isoniazid, rifampicin, D-penicillamine, sulfasalazine, clozapine, thioridazine, allopurinol, indomethacin, atorvastatin, cocaine/levamisole, denosumab, isotretinoin, and phenytoin [6]. Because of the low incidence of drug-induced ANCA-associated vasculitis and the beneficial use of the previously mentioned drugs, there is no recommendation to preclude the use of these medications. Because drug-induced vasculitis can cause rapidly deleterious disease, increasing awareness of it may lead to earlier diagnosis and prevent severe organ damage and death [7].
Hydralazine is one of the most common causes of drug-induced ANCA-associated vasculitis. A study performed by Kumar et al in 2018 [2] revealed that of 323 patients with ANCA-associated vasculitis, 12 were exposed to hydralazine, with the average duration of hydralazine therapy being 22 months and a mean cumulative dose of 146 g. In these patients, the serologic features overlapped with SLE, as all 12 were found to be positive for ANA (titers 1: 160 to 1: 2560; 10 diffuse pattern and 2 nucleolar), ANCA (titers 1: 320 to 1: 2560; 11 perinuclear ANCA pattern, 1 cytoplasmic ANCA), and anti-histone. Eleven of the 12 patients also were positive for anti-MPO and anti-double stranded DNA (anti-dsDNA), 4 had positive anti-cardiolipin IgG or IgM, and 9 had hypocomplementemia. All 6 patients who underwent kidney biopsy had pauci-immune crescentic glomerulonephritis. A literature review performed by Battisha et al in 2020 [8] showed that of 35 patients with lung-kidney syndrome secondary to hydralazine-induced, ANCA-associated vasculitis, 29 of 33 had positive ANA, 33 of 34 had positive anti-MPO, 6 of 19 had positive anti-PR3, 20 of 21 had positive anti-histone, and 12 of 30 had positive anti-dsDNA antibodies; 9 of 22 had low C3 and C4; none of 13 had anti-GBS antibodies; and 25 of 33 survived.

In our case, because the patient had no symptoms and only her kidneys were involved, it was challenging to reach the final diagnosis. There were 4 possible differentials: hydrazaline-induced lupus (HIL), idiopathic ANCA-associated vasculitis, SLE, and diabetic nephropathy or monoclonal Ig deposition disease. HIL usually occurs after use of medication for > 3 years in patients who are positive for ANA and anti-histone antibodies, and sometimes positive for anti-MPO antibodies [9]. However, HIL usually presents with systemic symptoms and sometimes arthritis (80% to 95%), kidney involvement is uncommon (<5%), and testing for anti-dsDNA antibodies usually is negative [9]. Unlike HIL, hydralazine-induced ANCA vasculitis is frequently associated with kidney involvement with a pauci-immune glomerulonephritis and high titers of anti-MPO [10]. In our case, high-titer anti-MPO (>4 times the normal value) was reassuring about the true-positive ANCA. Even though HIL can present with positive ANCA, the presence of pauci-immune glomerulonephritis instead of immune complex deposits on kidney biopsy helped us to make a definitive diagnosis. While lupus nephritis usually presents with immune complex deposits when kidney function is severely impaired (class III, IV, V, and VI), biopsy would show an immunofluorescence profile with staining for IgG, IgA, C3, and C1q. However, the renal biopsy in our patient only showed weak, nonspecific IgM. Active lupus nephritis would also be expected to show endocapillary proliferation and wire loops and/or hyaline thrombi, which were mentioned as pertinent negatives in our patient’s kidney biopsy.

Anti-histone, anti-dsDNA, and anti-cardiolipin antibodies usually are absent in idiopathic disease. Cessation of hydralazine significantly improved our patient’s kidney function, which makes drug-induced vasculitis a more probable diagnosis.

SLE typically progresses gradually. Patients with it are usually younger and almost always have other organ involvement, leukopenia and thrombocytopenia with anemia, low levels of C3 and C4, and are negative for anti-histone and ANCA antibodies but positive for anti-dsDNA and anti-Smith antibodies. In addition, in patients with SLE, kidney biopsy should reveal the classic findings of lupus nephritis described previously.

In our patient, the thickening of the glomerular and tubular basement membranes and the mesangial expansion/hypercellularity shown in the kidney biopsy were likely secondary to diabetes, but these relatively early diabetic features would not account for the rapid renal dysfunction or crescents. Her relatively well-controlled hemoglobin A1C over the past 5 years and normal serum immunofixation study excluded these diagnoses.

A PubMed search on January 10, 2021 using the search terms “hydralazine” and “ANCA vasculitis” retrieved records for only 50 published cases of hydralazine-induced, ANCA-associated vasculitis. Therefore, hydralazine-induced ANCA vasculitis is a very uncommon condition. The diagnosis mostly relies on serologic studies that are positive for ANCA (anti-MPO and/or anti-PR3) and tissue biopsy of involved organs that shows pauci-immune vasculitis. Some patients may test positive for anti-histone, anti-dsDNA, and anti-cardiolipin antibodies. It has been observed that patients with hydralazine-induced vasculitis typically have a more severe course than those with hydralazine-induced SLE, predominantly due to more kidney involvement with vasculitis; thus, they require more aggressive treatment [11]. The clinical manifestations of hydralazine-induced, ANCA-associated vasculitis depend on the organ involved and include dyspnea, cough, sinusitis, hemoptysis, paroxysmal nocturnal dyspnea, orthopnea, fatigue, general weakness, edema, fever, dizziness, altered mental status, near syncope, weight loss, decreased appetite, vomiting, hypertension, dysuria, hematuria, skin rash or erosion, hemorrhagic blisters, vesiculobullous lesions, pruritis, arthralgia, myalgia, sore throat, mouth ulcer, otalgia, and hepato-splenomegaly, with the complications of kidney failure, anemia, leukopenia, pancytopenia, alveolar hemorrhage, lung-kidney syndrome, pericarditis, and cutaneous vasculitis.

Kidney involvement is common in hydralazine-induced vasculitis. According to the 50 cases in our literature search, 16 of the patients had kidney biopsies, all of which showed pauci-immune glomerulonephritis. Light microscopy indicated crescent glomerulonephritis in 15 of the patients, combined segmental necrotizing lesions in 8 of them, and acute tubular injury or necrosis in 5 of those patients. Immunofluorescence studies showed mesangial hypercellularity in 5 of the patients.
So far, however, only 3 studies have reported hydralazine-induced vasculitis limited to the kidneys [3-5]. Only 1 study has reported on an asymptomatic patient with hydralazine-induced vasculitis [4]. The case we reported is of an asymptomatic patient with a negative prior urine microalbumin level, who was found to have hydralazine-induced, ANCA-associated, pauci-immune crescentic glomerulonephritis with a presentation limited to the kidneys. The findings in our patient highlight the need for increased awareness on the part of healthcare providers who are using hydralazine to treat hypertension, especially in patients who are asymptomatic and have worsening kidney function.

Withdrawal of the offending agent is always the primary intervention for hydralazine- or drug-induced ANCA vasculitis and initiation of immunosuppressive therapy is also considered the hallmark of management. Treatment should be individualized to the patient, based on age, disease severity, comorbidities, and kidney function on presentation [12]. Steroids were used in all the cases documented in the literature, as well as other immunosuppressants. Commonly used immunosuppressive therapy includes azathioprine, cyclophosphamide, mycophenolate mofetil, and rituximab [8,12,13]. Plasmapheresis was also used on some patients. Hemodialysis is often applied when there is progression to end-stage kidney disease or if severe hyperkalemia develops [3]. However, progression of kidney disease can still vary, and it sometimes results in poor outcomes despite medical therapy [14]. One study showed remission and relapse of kidney failure despite proper medical management [4]. Nonetheless, it remains crucial to have a high index of suspicion to diagnose and treat hydralazine-induced vasculitis promptly [14].

Conclusions

Hydralazine is widely prescribed during medical encounters. Hydralazine-induced, ANCA-associated vasculitis is still considered a rare disease, and as such, it can be misdiagnosed or neglected during medical practice. The clinical manifestations are varied. Patients can even be asymptomatic with pauci-immune crescentic glomerulonephritis as a kidney-limited presentation, as illustrated by the present case report. The diagnosis is challenging. Biopsy is helpful for making a definitive diagnosis, and especially for differentiating between drug-induced SLE and vasculitis. Early diagnosis, cessation of the offending drug, and initiation of immunosuppressive therapy are key to a favorable prognosis.

References:

1. Babar F, Posner JN, Obah EA. Hydralazine-induced pauci-immune glomerulonephritis. Intriguing case series with misleading diagnoses. J Community Hosp Intern Med Perspect. 2016;6(2):30632
2. Kumar B, Strouse J, Swee M, et al. Hydralazine-associated vasculitis: Overlapping features of drug-induced lupus and vasculitis. Semin Arthritis Rheum. 2018;48(2):283-87
3. Zuckerman R, Patel M, Costanzo EJ, et al. Hydralazine associated adverse event: A report of two cases of hydralazine induced ANCA vasculitis. J Bras Nefrol. 2018;40(2):193-97
4. Shida H, Hashimoto N, Kusunoki Y, et al. Anti-neutrophil extracellular trap antibody in a patient with relapse of anti-neutrophil cytoplasmic antibody-positive vasculitis. Mod Rheumatol. 2009;19(3):338-47
5. Baloch NU, Ibeabuchi AN. Hydralazine-induced MPO-ANCA renal-limited vasculitis masquerading as lupus nephritis. J Coll Physicians Surg Pak. 2018;28(11):896-97
6. Weng CH, Liu ZC. Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Chinese Med J. 2019;132(23):2848-55
7. Grau RG. Drug-induced vasculitis: New insights and a changing lineup of suspects. Curr Rheumatol Rep. 2015;17(12):71
8. Battisha A, Doughem K, Sheikh O, et al. Hydralazine-induced ANCA associated vasculitis (AAV) presenting with pulmonary-renal syndrome (PRS): A case report with literature review. Curr Cardiol Rev. 2020 [Online ahead of print]
9. Vaglio A, Grayson PF, Fenaroli P, et al. Drug-induced lupus: Traditional and new concepts. Autoimmun Rev. 2018;17(9):912-18
10. Choi HK, Merkel PA, Walker AM, et al. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: Prevalence among patients with high titers of antimeylperoxidase antibodies. Arthritis Rheum. 2000;43(2):405-13
11. Yokogawa N, Vivino FB. Hydralazine-induced autoimmune disease: Comparison to idiopathic lupus and ANCA-positive vasculitis. Mod Rheumatol. 2009;19(3):338-47
12. Aeddula NR, Pathireddy S, Ansari A, et al. Hydralazine-associated antineutrophil cytoplasmic antibody-positive vasculitis with pulmonary-renal syndrome. BMJ Case Rep. 2018;2018:bcr2018227161
13. Paley MA, Edrees F, Kudose S, et al. Successful use of rituximab for hydralazine-induced anti-neutrophil cytoplasmic antibodies-associated vasculitis. Saudi J Kidney Dis Transpl. 2019;30(1):226-30
14. Timlin H, Liebowitz JE, Jaggi K, et al. Outcomes of hydralazine induced renal vasculitis. Eur J Rheumatol. 2018;5(1):5-8